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ABSTRACT  
Epigenetic inactivation of tumor suppressor genes by 
promotor methylation is an important mechanism 
contributing to tumor progression. An example of a tumor 
suppressor gene which is frequently epigenetically 
inactivated in many types of cancer is RASSF1A. We 
analyzed promotor methylation of RASSF1A in uveal 
melanoma, the most common ocular malignancy. In this 
report we present an advanced approach to study quantity 
and density of methylation by combining methylation-
specific digestion with digital droplet PCR. High dense 
methylation appeared to be associated with loss of 
expression and is possibly related to metastatic 
progression despite lack of an established prognostic 
marker (monosomy 3). 
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INTRODUCTION 
Understanding of mechanisms leading to tumor 
development and progression are important to effectively 
combat cancer. In healthy cells, the action of tumor 
suppressor proteins is essential to prevent uncontrolled 
cell proliferation. In cancer cells, inactivation of tumor 
suppressor genes remove this restraint.1 Epigenetic 
inactivation by gene hypermethylation is one of the 
mechanisms leading to tumor suppressor gene 
inactivation.2 By adding methyl groups to promotor 
DNA, the availability of DNA sequences for expression is 
modified. Epigenetic gene inactivation leads to loss of 
expression and thereby to absence of the tumor 
suppressor protein, driving tumor progression.  
 
Figure 1. Schematic illustration of DNA methylation. 
Whereas analyzing inactivating mutations is nowadays 
straightforward and powerful as a result of technical 
development, the study of epigenetics is more 
complicated. In this paper, we present a new and unique 
approach to determine methylation status of tumor 
suppressor genes in tumors. More specifically, we studied 
methylation of the tumor suppressor gene Ras association 
domain family 1A (RASSF1A) in uveal melanoma (UM). 
Uveal melanoma is the most common ocular neoplasm. 
The tumor derives from uveal melanocytes of the iris, 
ciliary body or choroid plexus of the eye and has a strong 
tendency to metastasize to the liver. About 50% of the 
patients develop metastases, resulting in a high morbidity 
and mortality.3 Based on gene expression, uveal 
melanoma can be divided into two classes (fig. 2).4 Class 
I tumors usually do not metastasize and therefore have a 
favorable prognosis, while patients with class II tumors 
frequently develop metastatic disease. Class II tumors are 
characterized by the loss of one chromosome 3 
(monosomy 3). Monosomy 3 is strongly associated with a 
poor prognosis5, which suggests the involvement of 
tumor suppressor gene inactivation. A candidate tumor 
suppressor gene located on chromosome 3 is RASSF1A. 
This gene has been reported to be epigenetically 
inactivated in a wide variety of cancers.6 
 
Figure 2. Survival analysis of uveal melanoma patients. 
Classes are defined based on gene expression. 
Using a combination of methylation specific restriction 
enzymes and digital droplet PCR, we were able to 
quantify RASSF1A promotor methylation in uveal 
melanoma and correlate this with RASSF1A expression.  
We hypothesized to find RASSF1A methylation mainly 
in class II tumors. In these tumors, inactivation of one 
RASSF1A copy in combination with loss of the other 
chromosome 3 copy might have contributed to the 
development of metastases. 
MATERIALS AND METHODS 
Methylation analysis 
In order to analyze methylation status, we combined 
methylation specific digestion and digital droplet PCR 
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 (ddPCR) to analyze a RASSF1A promotor CpG island 
fragment. We obtained tumor material from 64 
enucleated eyes from uveal melanoma patients. Further 
analyses were performed using isolated DNA derived 
from these uveal melanoma.  
Two different assays were compared: ddPCR combined 
with Mspa1I digestion versus ddPCR combined with 
BstUI digestion. Mspa1I recognizes one sequence in the 
RASSF1A promotor fragment. All fragments which are 
unmethylated at this cytosine were digested by Mspa1I, 
whereas methylated fragments were resistant to digestion. 
Thereby, only fragments with methylation at the specific 
cytosine were available for amplification. Consequently, 
this assay determines minimal methylation. The 
recognition sequence of BstUI, in contrast, is present at 4 
locations in the RASSF1A promotor fragment. Only 
when all four cytosines were methylated, digestion by 
BstUI is prevented. Consequently, only fragments with 
four methylated cytosines were available for 
amplification, providing an indication of dense 
methylation (fig. 3).  
 
Figure 3. Schematic overview of DNA digestion by BstUI. 
After digestion with either Mspa1I or BstUI, ddPCR was 
performed. Each PCR reaction was fractionated into 
20.000 droplets. In each droplet, PCR amplification and 
characterization of the DNA fragment of interest and a 
stable reference gene took place. Subsequently, droplets 
were read and counted in micro flow, providing an 
absolute quantification.  
 
Figure 4. Two color ddPCR output. In order to determine 
methylated fraction, the amount of droplets positive for 
methylated RASSF1A is compared with the amount of 
droplets positive for the reference gene. 
Bisulfite conversion and sequencing 
In order to validate methylation with another method, UM 
DNA samples were bisulfite converted and sequenced by 
Sanger sequencing. Upon bisulfite conversion, 
unmethylated cytosines were converted to thymidines, 
while methylated cytosines were protected against 
bisulfite conversion. 
Expression analysis 
RNA was isolated from the same uveal melanoma 
material as described above. RNA was converted into 
cDNA in order to analyze RASSF1A expression. Real 
Time quantitative PCR (RT-qPCR) was used to 
determine the quantity of RASSF1A mRNA for each 
UM, providing an expression value.  
RESULTS 
Heterogeneity of RASSF1A methylation 
RASSF1A methylation status of each individual uveal 
melanoma was determined based on ddPCR combined 
with methylation specific digestion. The ddPCR assay 
combined with Mspa1I digestion, based on the 
methylation of one cytosine, revealed all uveal melanoma 
contained a certain amount of minimal methylation. 
When uveal melanoma were analyzed with BstUI 
digestion followed by ddPCR, based on the methylation 
of four cytosines, a different pattern was observed: only a 
few uveal melanoma presented with dense RASSF1A 
methylation (fig. 5A).  
Methylation status could be confirmed by sequencing of 
bisulfite converted DNA. In tumors with a low densely 
methylated fraction, all cytosines were converted into 
thymidines (fig. 5B), whereas in tumors with a high 
densely methylated fraction, cytosines of CpG sites were 
protected against conversion (fig. 5C) 
 
Figure 5. (A) Methylation status based on two different 
assays. (B) Sequence fragment after bisulfite conversion 
of a UM with a low dense methylation status (BstUI). All 
cytosines are replaced by thymidines. (C) Sequence 
fragment after bisulfite conversion of a UM with a high 
dense methylation status (BstUI). Methylated cytosines 
are preserved after conversion.  
RASSF1A expression is correlated with dense 
methylation status 
In order to evaluate whether methylation status as 
determined by our approach is associated with loss of 
RASSF1A expression, we performed expression analysis. 
RASSF1A expression appeared not to be correlated with 
minimal methylation status, determined by Mspa1I 
digestion combined with ddPCR; although minimal 
methylation was found in all UM, many tumors still 
expressed RASSF1A. In contrast, RASSF1A expression 
was well correlated with dense methylation status, 
determined by BstUI digestion combined with ddPCR. 
Most UM with a dense RASSF1A methylation status 
lower than 5% presented with RASSF1A transcripts, 
whereas most tumors with a dense RASSF1A 
methylation status above 5% lost RASSF1A expression 
or showed a greatly reduced expression (fig. 6). 
This threshold of 5% established by expression analysis 
was used to define dense methylation status; dense 
methylation status below 5% was defined as low, whereas 
dense methylation above 5% was defined as high.  
 
Figure 6. RASSF1A expression in UM with a low versus 
high dense methylation status. Methylation status above 
5% is correlated with loss of expression. Three outliers 
were observed (arrows).  
Explanation of outliers 
Three UM cases did not correspond with the overall 
observed pattern where high dense methylation status 
(>5%) was correlated with loss of expression. For two 
outliers, we were able to find a possible underlying 
mechanism. Outlier 1 (fig. 6, blue arrow) presented with a 
low methylation status (2%) in combination with loss of 
RASSF1A expression. Aberrant fluorescent signals in 
ddPCR data observed in this UM lead to the discovery of 
a single nucleotide polymorphism (SNP) in the 
RASSF1A promotor region.  
 
 
Figure 7. SNP in the RASSF1A promotor fragment 
recognized by the probe used in ddPCR. At position c.84 
a thymidine is replaced by an adenosine (c.84T>A). 
Outlier 2 presented with RASSF1A expression, despite of 
a high dense methylation status (63%). The melting 
temperature of cDNA derived from outlier 2 (~80 °C) 
deviated from the melting temperature of cDNA derived 
from other UM (~85 °C), indicating absence of 
RASSF1A cDNA outlier 2.  
Clinical significance of RASSF1A methylation in UM 
In order to study clinical significance of RASSF1A 
methylation in uveal melanoma, minimal as well as dense 
methylation status were compared between class I and II 
uveal melanoma. Minimal methylation was randomly 
distributed between class I and II tumors, suggesting 
absence of any clinical significance (fig. 8). 
Minimal RASSF1A methylation
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Figure 8. Random distribution of minimal RASSF1A 
methylation in class I and II. 
On the contrary, a high dense RASSF1A methylation 
status (>5%) appeared to be predominantly present in 
class I tumors (fig. 9). 
Dense RASSF1A methylation
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Figure 9. Dense RASSF1A methylation is more frequent 
in class I UM compared to class II. 
CONCLUSION 
In this study, RASSF1A methylation was analyzed using 
a new and unique approach. Digital droplet PCR in 
combination with methylation specific digestion gave an 
absolute quantification of methylation and information 
about methylation density.  
By analyzing minimal as well as dense methylation status 
in 64 uveal melanoma, different methylation frequencies 
were observed. The ddPCR assay combined with Mspa1I 
digestion revealed a high frequency of minimal 
 methylation in all uveal melanoma, while the ddPCR 
assay combined with BstUI digestion demonstrated a low 
frequency of dense methylation.  
By correlating RASSF1A expression with generated 
methylation status, the most informative approach to 
study methylation was determined. Minimal methylation 
status did not correlate with RASSF1A expression, 
whereas dense methylation status was well correlated 
with expression. This means minimal methylation, 
present in every uveal melanoma to a greater or lesser 
extent, does not provide any information about epigenetic 
inactivation of RASSF1A, while dense methylation does.  
No perfect correlation between dense methylation status 
and RASSF1A expression was observed due to the 
presence of three outliers. However, for two of those a 
possible explanation was found. Further experiments 
could give more insight into the underlying mechanisms. 
In one of the outliers, a SNP was observed in the 
RASSF1A promotor region, which might have caused the 
loss of expression in this tumor. This finding, together 
with the low occurrence of the SNP in the general 
population (< 1%) and the fact that the same SNP has 
also been described in a breast cancer patient7, support 
the functionality and clinical relevance of this SNP.  
As predicted by the functional uninformative character of 
minimal methylation, no clinical significance was 
observed. Minimal methylation status was randomly 
distributed between class I and class II tumors. In 
contrast, dense methylation predominantly occurred in 
class I tumors, representing mainly uveal melanoma with 
disomy 3. This contradicted our hypothesis, which was to 
find RASSF1A methylation mainly in class II tumors. 
Apparently, RASSF1A methylation is not involved in late 
tumor progression after the tumor has lost one 
chromosome 3 copy and does not contribute to the 
development of metastases in monosomy 3 tumors.  
The impact of dense RASSF1A methylation for class I 
patients is still unclear. Interestingly, of the four class I 
patients who developed metastatic disease, despite their 
good prognosis and disomy 3 status, three patients had a 
high dense RASSF1A methylation status (>5%). This 
suggests RASSF1A inactivation could be involved in 
tumor progression in these specific class I cases. So far, 
no explanation has been found for the metastatic disease 
in these patients, which are the only four exceptions 
developing metastases in class I. However, nothing can 
be firmly concluded due to the small number of cases.  
In conclusion, digital droplet PCR in combination with 
BstUI digestion, analyzing dense methylation, is a good 
approach to study the inactivation of the RASSF1A gene, 
in contrast to ddPCR combined with Mspa1I. Thereby we 
present the first quantitative epigenetic marker that 
correlates and possibly explains RASSF1A expression in 
tumors. Moreover, we provide a possible explanation for 
metastatic progression in so far unexplained cases, 
namely class I metastatic UM patients.  
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